Status:
COMPLETED
Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Dementia
Eligibility:
MALE
18-40 years
Phase:
PHASE1
Brief Summary
The drug, scopolamine, can result in short-term impairments of cognitive function, attention, and memory that resemble those seen in aging and Alzheimer's disease. This study tested the capability of ...
Eligibility Criteria
Inclusion
- Participants were eligible for inclusion in the study who were:
- Male between 18 and 40 years of age.
- Non-smokers, in good health (as defined in protocol), and were willing to follow study-related procedures.
- Participants were not eligible for inclusion in the study if they:
- Had a history of illness that, in the opinion of the study investigator or as specified in protocol, might confound the results of the study or posed an potential, additional risk to the participant if they were to participate in the study.
- Were taking any medication (prescription, nonprescription, vitamin supplements or herbal, illicit or legitimate) except for acetaminophen.
- Had a history of any significant head injury/trauma.
Exclusion
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01181310
Start Date
June 1 2007
End Date
October 1 2007
Last Update
November 6 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.